Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) with a $160 price target.
June 12, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $160.
The reiteration of an Overweight rating and a $160 price target by a reputable analyst from Morgan Stanley is likely to positively impact the stock price of Neurocrine Biosciences in the short term. This indicates continued confidence in the company's performance and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100